Company / Free Cash Flow
Dyne Therapeutics, Inc. Free Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$294.7M
FY2024
5-year range
-$294.7M / -$47.7M
FY2020-FY2024
Trend
-56.0%
vs FY2023
Sector context
#165 of 192
Health Care
What the data says
Dyne Therapeutics, Inc.'s free cash flow of -$295M is lower than 86% of companies in the Health Care sector (FY2024). Free Cash Flow has declined for 5 consecutive years, from -$13M in FY2019 to -$295M in FY2024.
Based on SEC 10-K filings.
-$295M in FY2024.
Declined from -$157M to -$295M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 192This company -$294.7M Sector average $474.2M
▼
-162.2% below sector average
Key checks
Key Insights
- Dyne Therapeutics, Inc.'s free cash flow has declined for 5 consecutive years.
- In FY2024, free cash flow decreased 56.0% year-over-year.
- Ranks #165 out of 192 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$294.7M | -56.0% |
| FY2023 | -$188.9M | -20.5% |
| FY2022 | -$156.7M | -27.2% |
| FY2021 | -$123.2M | -158.4% |
| FY2020 | -$47.7M | -253.6% |
| FY2019 | -$13.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026